Autoimmune mechanisms in myasthenia gravis

Current Opinion in Neurology

Volumn 25, Issue 5, 2012, Pages 621-629

  Cavalcante, Paola ^a   Bernasconi, Pia ^a   Mantegazza, Renato ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

autoantibodies; autoimmunity; myasthenia gravis; thymus

Indexed keywords

ANTIVIRUS AGENT; AUTOANTIBODY; AUTOANTIGEN; AZATHIOPRINE; BELIMUMAB; BORTEZOMIB; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C1Q ANTIBODY; CORTICOSTEROID; CYCLOSPORIN; ECULIZUMAB; EPSTEIN BARR VIRUS VACCINE; IMMUNOGLOBULIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 4; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ANTIVIRAL THERAPY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHRONIC INFLAMMATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG EFFICACY; ENVIRONMENTAL FACTOR; EPSTEIN BARR VIRUS INFECTION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; LONG TERM CARE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; ONSET AGE; PLASMAPHERESIS; PROTEIN ANALYSIS; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL; THYMECTOMY; THYMUS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ADRENAL CORTEX HORMONES; ANIMALS; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MYASTHENIA GRAVIS; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; NEUROMUSCULAR JUNCTION;

EID: 84866334495     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328357a829     Document Type: Review

References (90)

1. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002; 2:797-804. (Pubitemid 37328719)
2. Rose NR, Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 1993; 14:426-430. (Pubitemid 23271739)
3. Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest 2006; 116:2843-2854. (Pubitemid 44684466)
4. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 2008; 131:1940-1952. (Pubitemid 351957451)
5. Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 2003; 998:413-423. (Pubitemid 37194193)
6. Marx A, Wilisch A, Schultz A, et al. Pathogenesis of myasthenia gravis. Virchows Archiv 1997; 430:355-364. (Pubitemid 27202101)
7. Leite MI, Strobel P, Jones M, et al. Fewer thymic changes in MuSK antibodypositive than in MuSK antibody-negative MG. Ann Neurol 2005; 57:444-448. (Pubitemid 40343969)
8. Mantegazza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat 2011; 7:151-160.
9. Colleoni L, Kapetis D, Maggi L, et al. A new thiopurine S-methyltransferase haplotype associated with intolerance to azathioprine. J Clin Pharmacol 2012 [Epub ahead of print].
10. Drachman DB, Adams RN, Josifek LF, Self SG. Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis. N Engl J Med 1982; 307:769-775. (Pubitemid 12061550)
11. Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve 2011; 44:36-40.
12. Oshima M, Deitiker PR, Smith RG, et al. T-cell recognition of acetylcholine receptor provides a reliable means for monitoring autoimmunity to acetylcholine receptor in antibody-negative myasthenia gravis patients. Autoimmunity 2012; 45:153-160.
13. Maggi L, Andreetta F, Antozzi C, et al. Thymoma-associated myasthenia gravis: outcome, clinical and pathological correlations in 197 on a 20-year experience. J Neuroimmunol 2008; 202:237-244.
14. Suzuki S, Utsugisawa K, Nagane Y, Suzuki N. Three types of striational antibodies in myasthenia gravis. Autoimmune Dis 2011; 2011:740583.
15. Romi F, Suzuki S, Suzuki N, et al. Antivoltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012; 259:1312-1316.
16. Zhang B, Tzartos JS, Belimezi M, et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69:445-451.
17. Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to lowdensity lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol 2011; 69:418-422.
18. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR-and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259:427-435.
19. Kim N, Stiegler AL, Cameron TO, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell 2008; 135:334-342.
20. Zhang B, Luo S, Wang Q, et al. LRP4 serves as a coreceptor of agrin. Neuron 2008; 60:285-297.
21. Vaknin-Dembinsky A, Abramsky O, Petrou P, et al. Myasthenia gravis-associated neuromyelitis optica-like disease: an immunological link between the central nervous system and muscle? Arch Neurol 2011; 68:1557-1561.
22. Jarius S, Paul F, Franciotta D, et al. Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 2012; 18:1135-1143.
23. Vincent A, Willcox N, Hill M, et al. Determinant spreading and immune responses to acetylcholine receptors in myasthenia gravis. Immunol Rev 1998; 164:157-168. (Pubitemid 28438405)
24. Luo J, Lindstrom J. Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors. Autoimmunity 2012; 45:245-252.
25. Wu X, Tuzun E, Li J, et al. Ocular and generalized myasthenia gravis induced by human acetylcholine receptor g subunit immunization. Muscle Nerve 2012; 45:209-216.
26. Richman DP, Nishi K, Morell SW, et al. Acute severe animal model of antimuscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes. Arch Neurol 2012; 69:453-460.
27. Viegas S, Jacobson L, Waters P, et al. Passive and active immunization models of MuSK-Ab positive myasthenia: Electrophysiological evidence for pre and postsynaptic defects. Exp Neurol 2012; 234:506-512.
28. Mori S, Kubo S, Akiyoshi T, et al. Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis. Am J Pathol 2012; 180:798-810.
29. Kawakami Y, Ito M, Hirayama M, et al. Anti-MuSK autoantibodies block binding of collagen Q to MuSK. Neurology 2011; 77:1819-1826.
30. Klooster R, Plomp JJ, Huijbers MG, et al. Muscle-specific kinase myasthenia gravis IgG4 autoantibodies cause severe neuromuscular junction dysfunction in mice. Brain 2012; 135:1081-1101.
31. Vandiedonck C, Giraud M, Garchon HJ. Genetics of autoimmune myasthenia gravis: the multifaceted contribution of the HLA complex. J Autoimmun 2005; 25:6-11. (Pubitemid 41728036)
32. Baggi F, Antozzi C, Andreetta F, et al. Identification of a novel HLA class II association with DQB1-0502 in an Italian myasthenic population. Ann NY Acad Sci 1998; 841:355-359.
33. Niks EH, Kuks JB, Roep BO, et al. Strong association of MuSK antibodypositive myasthenia gravis and HLA-DR14-DQ5. Neurology 2006; 66:1772-1774. (Pubitemid 43964645)
34. Deitiker PR, Oshima M, Smith RG, et al. Association with HLA DQ of early onset myasthenia gravis in Southeast Texas region of the United States. Int J Immunogenet 2011; 38:55-62.
35. Giraud M, Taubert R, Vandiedonck C, et al. An IRF8-binding promoter variant and AIRE control CHRNA1 promiscuous expression in thymus. Nature 2007; 448:934-937. (Pubitemid 47312776)
36. Gregersen PK, Lee HS, Batliwalla F, Begovich AB. PTPN22: setting thresholds for autoimmunity. Semin Immunol 2006; 18:214-223. (Pubitemid 43903284)
37. Menard L, Saadoun D, Isnardi I, et al. The PTPN22 allele encoding an R620W variant interferes with the removal of developing autoreactive B cells in humans. J Clin Invest 2011; 121:3635-3644.
38. Zhang J, Zahir N, Jiang Q, et al. The autoimmune disease-associated PTPN22 variant promotes calpain-mediated Lyp/Pep degradation associated with lymphocyte and dendritic cell hyperresponsiveness. Nat Genet 2011; 43:902-907.
39. Provenzano C, Ricciardi R, Scuderi F, et al. PTPN22 and myasthenia gravis: replication in an Italian population and meta-analysis of literature data. Neuromuscul Disord 2012; 22:131-138.
40. Vandiedonck C, Capdevielle C, Giraud M, et al. Association of the PTPN22-R620W polymorphism with autoimmune myasthenia gravis. Ann Neurol 2006; 59:404-407.
41. Schwimmbeck PL, Dyrberg T, Drachman DB, Oldstone MBA. Molecular mimicry and myasthenia gravis. An autoantigenic site of the acetylcholine receptor alpha-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989; 84:1174-1180. (Pubitemid 19247588)
42. Marino Gammazza A, Bucchieri F, Grimaldi LM, et al. The molecular anatomy of human Hsp60 and its similarity with that of bacterial orthologs and acetylcholine receptor reveal a potential pathogenetic role of antichaperonin immunity in myasthenia gravis. Cell Mol Neurobiol 2012; 32:943-947.
43. Tindall RSA, Cloud R, Lucky J, Rosenberg RN. Serum antibodies to cytomegalovirus in myasthenia gravis: effects of thymectomy and steroids. Neurology 1978; 28:273-277. (Pubitemid 8312876)
44. Klavinskis LS, Willcox N, Newsom-Davis J. Antivirus antibodies in myasthenia gravis. Neurology 1985; 35:1381-1384. (Pubitemid 15021612)
45. Aoki T, Drachman DB, Asher DM, et al. Attempts to implicate viruses in myasthenia gravis. Neurology 1985; 35:185-192. (Pubitemid 15171516)
46. Klavinski LS, Willcox HNA, Richmond JE, Newsom-Davis J. Attempted isolation of viruses from myasthenia gravis thymus. J Neuroimmunol 1986; 11:287-299. (Pubitemid 16061169)
47. McGuire LJ, Huang DP, Teoh R, et al. Epstein-Barr virus genome in thymoma and thymic lymphoid hyperplasia. Am J Pathol 1988; 131:385-390.
48. Manca N, Perandin F, De Simone N, et al. Detection of HTLVI tax-rex and pol gene sequences of thymus gland in large group of patients with myasthenia gravis. J Acquir Immune Defic Syndr 2002; 29:300-306. (Pubitemid 34208540)
49. Cavalcante P, Barberis M, Cannone M, et al. Detection of poliovirus-infected macrophages in thymus of patients with myasthenia gravis. Neurology 2010; 74:1118-1126.
50. Auriel E, Regev K, Dori A, Karni A. Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 2011; 43:893-894.
51. Hung WL, Lin YH, Wang PY, Chang MH. HIV-associated myasthenia gravis and impacts of HAART: one case report and a brief review. Clin Neurol Neurosurg 2011; 113:672-674.
52. Csuka D, Banati M, Rozsa C, et al. High anti-EBNA-1 IgG levels are associated with early-onset myasthenia gravis. Eur J Neurol 2012; 19: 842-846.
53. Cavalcante P, Serafini B, Rosicarelli B, et al. Epstein-Barr virus persistence and reactivation in myasthenia gravis thymus. Ann Neurol 2010; 67:726-738.
54. Cavalcante P, Maggi L, Colleoni L, et al. Inflammation and Epstein-Barr virus infection are common features of myasthenia gravis thymus: possible roles in pathogenesis. Autoimmune Dis 2011; 2011:213092.
55. Kakalacheva K, Maurer MA, Tackenberg B, et al. Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis. Ann Neurol 2011; 70:508-514.
56. Meyer M, Hö ls AK, Liersch B, et al. Lack of evidence for Epstein-Barr virus infection in myasthenia gravis thymus. Ann Neurol 2011; 70:515-518.
57. Serafini B, Cavalcante P, Bernasconi P, et al. Epstein-Barr virus in myasthenia gravis thymus: a matter of debate. Ann Neurol 2011; 70:519.
58. Cavalcante P, Le Panse R, Berrih-Aknin S, et al. The thymus in myasthenia gravis: site of 'innate autoimmunity'? Muscle Nerve 2011; 44:467-484.
59. Sims GP, Shiono H, Willcox N, Stott DI. Somatic hypermutation and selection of B cells in thymic germinal centers responding to acetylcholine receptor in myasthenia gravis. J Immunol 2001; 167:1935-1944. (Pubitemid 32747498)
60. Roxanis I, Micklem K, McConville J, et al. Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis. J Neuroimmunol 2002; 125:185-197. (Pubitemid 34327469)
61. Thangarajh M, Masterman T, Helgeland L, et al. The thymus is a source of B-cell survival factors-APRIL and BAFF-in myasthenia gravis. J Neuroimmunol 2006; 178:161-166. (Pubitemid 44316862)
62. Kyewski B, Klein L. A central role for central tolerance. Annu Rev Immunol 2006; 24:571-606.
63. Akirav EM, Ruddle NH, Herold KC. The role of AIRE in human autoimmune disease. Nat Rev Endocrinol 2011; 7:25-33.
64. Aricha R, Feferman T, Scott HS, et al. The susceptibility of Aire(-/-) mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 2011; 36:16-24.
65. Balandina A, Lé cart S, Dartevelle P, et al. Functional defect of regulatory CD4( +)CD25 + T cells in the thymus of patients with autoimmune myasthenia gravis. Blood 2005; 105:735-741. (Pubitemid 40070760)
66. Poëa-Guyon S, Christadoss P, Le Panse R, et al. Effects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol 2005; 174:5941-5949. (Pubitemid 40663780)
67. Marx A, Willcox N, Leite MI, et al. Thymoma and paraneoplastic myasthenia gravis. Autoimmunity 2010; 43:413-427.
68. Zhang M, Li H, Guo J, et al. Different molecular expression in thymoma with ocular or generalized myasthenia gravis. J Neurol Sci 2012; 313:27-31.
69. Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology 2012; 78:15-23.
70. Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204:2899-2912. (Pubitemid 350179559)
71. Crampton SP, Voynova E, Bolland S. Innate pathways to B-cell activation and tolerance. Ann N Y Acad Sci 2010; 1183:58-68.
72. Hackl D, Loschko J, Sparwasser T, et al. Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs. Eur J Immunol 2011; 41:1334-1343.
73. Bernasconi P, Barberis M, Baggi F, et al. Increased Toll-like receptor 4 expression in thymus of myasthenia gravis patients. AmJ Pathol 2005; 167:129-139. (Pubitemid 40884776)
74. Fiola S, Gosselin D, Takada K, Gosselin J. TLR9 contributes to the recognition of EBV by primary monocytes and plasmacytoid dendritic cells. J Immunol 2010; 185:3620-3631.
75. Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3 + regulatory T cells in systemic autoimmune diseases. Autoimmun Rev 2011; 10:744-755.
76. Kleczynska W, Jakiela B, Plutecka H, et al. Imbalance between Th17 and regulatory T-cells in systemic lupus erythematosus. Folia Histochem Cytobiol 2011; 49:646-653.
77. Niu Q, Cai B, Huang ZC, et al. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2011. [Epub ahead of print]
78. Ferraro A, Socci C, Stabilini A, et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011; 60:2903-2913.
79. Masuda M, Matsumoto M, Tanaka S, et al. Clinical implication of peripheral CD4 +CD25 + regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010; 225:123-131.
80. Aricha R, Mizrachi K, Fuchs S, Souroujon MC. Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 2011; 36:135-141.
81. Nessi V, Nava S, Ruocco C, et al. Naturally occurring CD4 +CD25 + regulatory T cells prevent but do not improve experimental myasthenia gravis. J Immunol 2010; 185:5656-5667.
82. Roche JC, Capablo JL, Larrad L. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve 2011; 44:278-280.
83. Na SJ, So SH, Lee KO, Choi YC. Elevated serum level of interleukin-32a in the patients with myasthenia gravis. J Neurol 2011; 258:1865-1870.
84. Chen Z, Luo H, Peng Y, et al. Comparative clinical features and immune responses after extended thymectomy for myasthenia gravis in patients with atrophic versus hyperplastic thymus. Ann Thorac Surg 2011; 91:212-218.
85. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82:671-673.
86. Blum S, Gillis D, Brown H, et al. Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82:659-663.
87. Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78:189-193.
88. Gomez AM, Vrolix K, Martínez-Martínez P, et al. Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 2011; 186:2503-2513.
89. Christadoss P, Tuzun E, Li J, et al. Classical complement pathway in experimental autoimmune myasthenia gravis pathogenesis. Ann N Y Acad Sci 2008; 1132:210-219. (Pubitemid 351841352)
90. Howard J, Barhon R, Freimer M, et al. Randomized, double-blind, placebocontrolled, crossover, multicenter, Phase II study of eculizumab in patients with refractory generalized myasthenia gravis [abstract]. Neurology 2012; 78:S35.0054